Edition:
India

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

17.98USD
5 Jun 2020
Change (% chg)

$0.12 (+0.67%)
Prev Close
$17.86
Open
$18.39
Day's High
$18.89
Day's Low
$17.78
Volume
373,671
Avg. Vol
463,556
52-wk High
$37.00
52-wk Low
$10.09

Select another date:

Tue, Mar 17 2020

Aimmune sees coronavirus slowing down marketing of peanut allergy therapy

Aimmune Therapeutics Inc on Monday warned of a slow launch of its peanut allergy therapy, as its marketing plans take a hit from U.S. authorities' recommendation of social distancing to contain the spread of the coronavirus.

UPDATE 2-Aimmune sees coronavirus slowing down marketing of peanut allergy therapy

March 16 Aimmune Therapeutics Inc on Monday warned of a slow launch of its peanut allergy therapy, as its marketing plans take a hit from U.S. authorities' recommendation of social distancing to contain the spread of the coronavirus.

Aimmune sees slowdown in launch of peanut allergy therapy due to coronavirus

Aimmune Therapeutics Inc said on Monday the launch of its peanut allergy therapy may be slowed by the spread of coronavirus in the United States.

Aimmune says peanut allergy therapy launch may be slowed down by coronavirus

March 16 Aimmune Therapeutics Inc on Monday said the launch of its peanut allergy therapy may be slowed down by the spread of the coronavirus in the United States.

BRIEF-Aimmune Announces First U.S. Patients Are Being Treated With Newly-Approved Palforzia, The First Treatment For Peanut Allergy

* AIMMUNE ANNOUNCES FIRST U.S. PATIENTS ARE BEING TREATED WITH NEWLY-APPROVED PALFORZIA™, THE FIRST TREATMENT FOR PEANUT ALLERGY Source text for Eikon: Further company coverage:

BRIEF-Aimmune Announces New Palforzia Data After 18 And 24 Months Of Treatment

* AIMMUNE ANNOUNCES NEW PALFORZIA™ DATA SUGGESTING INCREASED DESENSITIZATION, IMPROVED TOLERABILITY AND CONTINUED IMMUNOMODULATION AFTER 18 AND 24 MONTHS OF TREATMENT

Nestle invests $200 million more in Aimmune after peanut allergy drug approval

Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted as a potential blockbuster.

UPDATE 3-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval

Feb 5 Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted as a potential blockbuster.

Nestle invests $200 million more in Aimmune after peanut allergy drug approval

Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted as a potential blockbuster.

Nestle raises stake in Aimmune after peanut allergy therapy approval

Feb 5 Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million in the drugmaker, bringing the Swiss company's total investment to $473 million.

Select another date: